Monday, March 8, 1993
Raab presses ahead in D.C.
WASHINGTON - Genentech Inc. chief executive G. Kirk Raab last
week launched his campaign to bring a distinct biotech perspective to the White
House, and was to continue this week pressing the industry's case on drug pricing
and technology transfer.
Raab held a series of high-level discussions with White House
staff, Clinton administration members including members of the health care reform
task force, and members of Congress in hopes of discouraging new pricing or
technology licensing policies that would injure the biotechnology industry.